## First-Line Treatment of Symptomatic CLL (Fit Patient, del(17p)-Negative) **Key Point:** Venetoclax (BCL-2 inhibitor) combined with obinutuzumab (anti-CD20 monoclonal antibody) is the current standard first-line regimen for fit patients with symptomatic CLL, regardless of del(17p) status, based on the CLL14 trial. ### Rationale for Venetoclax + Obinutuzumab **High-Yield:** The CLL14 trial (2019) demonstrated that venetoclax + obinutuzumab achieves superior progression-free survival (PFS) and minimal residual disease (MRD) negativity compared to chlorambucil + obinutuzumab, even in del(17p)-negative disease. ### Treatment Paradigm Shift | Regimen | Mechanism | PFS | MRD Negativity | Fit Status | Current Role | |---------|-----------|-----|----------------|-----------|---------------| | **Venetoclax + Obinutuzumab** | BCL-2 inhibitor + anti-CD20 | 70–80% at 3 yr | 60–70% | Fit | **First-line (all risk groups)** | | Ibrutinib | BTK inhibitor | 60–70% at 3 yr | 20–30% | Fit/unfit | Alternative first-line | | FCR | Chemoimmunotherapy | 50–60% at 5 yr | 40–50% | Fit only | Rarely used (toxicity in elderly) | | Chlorambucil + Obinutuzumab | Alkylator + anti-CD20 | 40–50% at 3 yr | 20–30% | Unfit | Unfit/elderly patients | **Clinical Pearl:** Venetoclax requires ramp-up dosing (5 mg → 400 mg over 5 weeks) to minimize tumor lysis syndrome risk; prophylaxis with allopurinol/febuxostat and hydration is mandatory. **Warning:** FCR, though historically landmark, is now avoided in fit patients due to cumulative myelotoxicity and secondary malignancy risk; reserved only for highly selected young patients with favorable biology. ### Monitoring - Assess MRD by flow cytometry at end of treatment - MRD-negative status predicts superior long-term outcomes - Venetoclax is typically given for 12 months with obinutuzumab induction (6 cycles) **Mnemonic:** **VEnetoclax + OBinutuzumab = VO** is the modern first-line CLL regimen.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.